Objective:To observe the clinical efficacy of “Feiyanning Granule” in treating advanced lung cancer. Methods In this prospective, randomized and controlled trial, 60 non-small cell lung cancer patients with deficiency were randomly divided into treatment group and control group, 30 cases in each group. The treatment group was administered “Feiyanning Granule” for oral intake, while the control group took 10% of the dose of simultaneous treatment for 8 weeks. The clinical efficacy of solid tumor and changes of symptoms and syndrome in TCM and improvement of quality of life were observed, while the side effects and adverse reactions were monitored.  Results:①The effective rate was 66.67% and disease control rate was 70.00% in the treatment group, and they were 0.00% and 43.33% in the control group. There was a significant difference in the curative effect in solid tumor between the two groups(P<0.05). ②After treatment, the scores of domains in EORTC QLQ-LC30 were statistically higher in physical functions, emotional functions and general health(P<0.05), while they changed little in the control group, with significant differences between the two groups(P<0.05). ③The improvement of domains in the symptoms of breathlessness, cough, fatigue, pain and insomnia in the treatment group were obviously reduced(P<0.05); the pain score was increased in the control group(P<0.05) and other scores changed little(P>0.05); there were great differences in above symptoms between the two groups after treatment(P<0.05). ④ The incidence rate of adverse reaction was 16.67% and 26.67% respectively in the treatment group and control group, with no difference between them(P>0.05); there were no significant abnormality in the hematopoietic system and liver-kidney function in these two groups.  Conclusion:“Feiyanning Granule” is effective to elevate short-term efficacy in treating advanced lung cancer and improving the quality of life, without severe side effects.